Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Communications orales et posters

Communications et posters de la R&D d'Unicancer

2016

Efficacy of crizotinib in ALK+, MET+ or ROS1+ advanced pediatric malignancies: results of the AcSé phase II trial.

G. Vassal et al., SIOP2016

2016

Carcinomes épidermoïdes cutanés (CE) induits par le Vemurafenib (Vemu) chez les patients atteints de tumeurs non mélanocytaires

E. Maubec et al., Journées de Dermatologie de Paris 2016 (JDP)

2016

Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: first results of a prospective cohort from the French Breast Cancer In

Jean-Yves Pierga et al., SABCS

2016

Circulating Tumor Cells (CTC) and pathological complete response (pCR) are strong independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials of neoadjuvant chemotherapy combined with bevacizu

F. C. Bidard et al., ISMRC

2016

Comparison of Methotrexate-Etoposide-Ifosfamide and API-AI based regimen in 18-25yr osteosarcoma patients included in the French OS2006/Sarcome-09 study

V. Laurence et al., CTOS 2016

2016

Can Surrogate Pathological Subtyping Replace Molecular Subtyping? Outcome Results from the MINDACT Trial

Fatima Cardoso et al., SABCS

2016

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

Sandrine Hiret et al., ASCO 2016

2016

Busulfan-Melphalan with blood stem cell rescue (BuMel) for high risk localised Ewing Sarcoma (ES): results of R2Loc randomised study

Jeremy Whelan et al., CTOS 2016

2016

Biomarker-driven access to vemurafenib in BRAF positive cancers: second study of the French National AcSé Program.

Jean-Yves Blay et al., ASCO2016

2016

ASTER 70s ou Traitement adjuvant systémique du cancer du sein avec récepteurs aux oestrogènes-positifs et HER2-négatif de la femme de plus de 70 ans en fonction du grade génomique (GG)

Florence Coussy et al., SOFOG 2016